[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112014011609A2 - material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco - Google Patents

material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco

Info

Publication number
BR112014011609A2
BR112014011609A2 BR112014011609A BR112014011609A BR112014011609A2 BR 112014011609 A2 BR112014011609 A2 BR 112014011609A2 BR 112014011609 A BR112014011609 A BR 112014011609A BR 112014011609 A BR112014011609 A BR 112014011609A BR 112014011609 A2 BR112014011609 A2 BR 112014011609A2
Authority
BR
Brazil
Prior art keywords
drug delivery
delivering
delivery composition
producing same
aqueous solution
Prior art date
Application number
BR112014011609A
Other languages
English (en)
Inventor
Reiff Andreas
Voigt Andreas
Kriwanek Jörg
Hompton Scott
Lehmann Sonja
Original Assignee
Therakine Biodelivery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakine Biodelivery Gmbh filed Critical Therakine Biodelivery Gmbh
Publication of BR112014011609A2 publication Critical patent/BR112014011609A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo patente de invenção: "material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco". a presente invenção refere-se a um método para produção de uma composição de distribuição de fármaco, que inclui proporcionar pelo menos um composto farmaceuticamente ativo, um pó seco compreendendo pelo menos um polímero, e uma solução aquosa. o pó seco, o composto farmaceuticamente ativo e a solução aquosa são misturados para formar uma composição de distribuição de fármaco similar à pasta ou semissólida, no qual a solução aquosa é adicionada em uma quantidade de menos do que ou igual a duas vezes a massa seca total do pó seco.
BR112014011609A 2011-11-30 2012-11-29 material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco BR112014011609A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/307,474 US9474715B2 (en) 2011-11-30 2011-11-30 Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
PCT/EP2012/073983 WO2013079605A2 (en) 2011-11-30 2012-11-29 Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition

Publications (1)

Publication Number Publication Date
BR112014011609A2 true BR112014011609A2 (pt) 2017-05-30

Family

ID=47278823

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011609A BR112014011609A2 (pt) 2011-11-30 2012-11-29 material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco

Country Status (12)

Country Link
US (2) US9474715B2 (pt)
EP (1) EP2785330B1 (pt)
JP (1) JP2015502354A (pt)
KR (1) KR20140097541A (pt)
CN (1) CN104105480A (pt)
AU (1) AU2012343854A1 (pt)
BR (1) BR112014011609A2 (pt)
CA (1) CA2856794A1 (pt)
ES (1) ES2637379T3 (pt)
RU (1) RU2014126347A (pt)
SG (1) SG11201401770YA (pt)
WO (1) WO2013079605A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170290775A1 (en) * 2014-10-07 2017-10-12 Therakine Bio Delivery GmbH Micronized delivery material and methods for manufacturing thereof
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
GB201500430D0 (en) 2015-01-12 2015-02-25 Univ Birmingham Dressing
JP2020528931A (ja) * 2017-07-25 2020-10-01 ピーケイ・メッド・ソシエテ・パール・アクシオン・サンプリフィエＰｋ Ｍｅｄ Ｓａｓ 薬物送達組成物
MX2020003976A (es) * 2017-10-12 2020-10-01 Solyplus Gmbh Procesamiento mecanico de biopolimeros.
WO2019073363A1 (en) * 2017-10-12 2019-04-18 Solyplus Berlin Gmbh PROCESS FOR TREATING BIOPOLYMERS USING COMBINATIONS OF SOLVENTS
CN109529116B (zh) * 2019-01-29 2019-12-31 中国海洋大学 一种用于治疗烫伤的ns-gam基因活性支架及其制备方法
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
EP4069324A4 (en) 2019-12-06 2024-01-10 Guangzhou Bioseal Biotech Co., Ltd. FLUID FIBRINOGEN THROMBIN PASTE

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1540979A (en) 1923-04-11 1925-06-09 Swift & Co Machine for testing jelly strength of glues, gelatins, and the like
US5876754A (en) 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
JPH06218028A (ja) * 1992-10-02 1994-08-09 Eisai Co Ltd 湿製錠の成型方法とその装置及び湿製錠
CA2171607A1 (en) * 1993-09-20 1995-03-30 Conor John Graham Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
US5674495A (en) 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
FI103207B (fi) 1996-08-27 1999-05-14 Sune Backlund Immobilisoidun entsyymin sisältävä geeli
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
AU6318900A (en) * 1999-08-05 2001-03-05 Takeda Chemical Industries Ltd. Pastes with the sustained release of osteogenesis promoter
WO2001064164A2 (en) * 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
CN1993060A (zh) 2004-08-19 2007-07-04 帝斯曼知识产权资产管理有限公司 可脂溶物质的新型组合物
CN101132800A (zh) 2004-11-24 2008-02-27 席拉坎有限责任公司 一种用于眼内药物释出的植入体
MX2008015976A (es) 2006-06-12 2009-04-14 Therakine Ltd Tratamiento topico para enfermedades de superficie ocular.
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8927046B2 (en) 2009-02-04 2015-01-06 Dsm Ip Assets B.V. Resveratrol compositions

Also Published As

Publication number Publication date
WO2013079605A3 (en) 2013-08-29
US20170095419A1 (en) 2017-04-06
EP2785330A2 (en) 2014-10-08
KR20140097541A (ko) 2014-08-06
AU2012343854A1 (en) 2014-05-08
US20130136774A1 (en) 2013-05-30
EP2785330B1 (en) 2017-03-29
JP2015502354A (ja) 2015-01-22
WO2013079605A2 (en) 2013-06-06
ES2637379T3 (es) 2017-10-13
CN104105480A (zh) 2014-10-15
US9474715B2 (en) 2016-10-25
CA2856794A1 (en) 2013-06-06
SG11201401770YA (en) 2014-09-26
RU2014126347A (ru) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112014011609A2 (pt) material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
BR112015014372A2 (pt) inibidores de autotaxina
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
CR11441A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
BR112015000320A2 (pt) composições farmacêuticas dissuasivas de abuso, de liberação prolongada
EP4378959A3 (en) Formulation for anti-alpha4beta7 antibody
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
JP2016503398A5 (pt)
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
BR112013022448A2 (pt) estrutura com base em polietileno
BR112018011266A2 (pt) ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica?
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
BR112015005621A2 (pt) carbonato de hidróxido de magnésio como material veículo em preparações contendo ingredientes ativos
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
NZ708821A (en) Lfa-1 inhibitor formulations
BR112013001462B8 (pt) Composições
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
EA201391348A1 (ru) КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired